MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.
about
What is the Need for Prostatic Biomarkers in Prostate Cancer Management?Prognostic role of microRNA-205 in multiple human malignant neoplasms: a meta-analysis of 17 studiesMicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer.DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate CancerMicroRNA‑205 promotes the tumorigenesis of nasopharyngeal carcinoma through targeting tumor protein p53-inducible nuclear protein 1.Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients.Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.miR-205 suppresses the proliferative and migratory capacity of human osteosarcoma Mg-63 cells by targeting VEGFA.The miR-30 family: Versatile players in breast cancer.Targeting MicroRNAs in Prostate Cancer Radiotherapy.MicroRNA expression profiling in canine prostate cancer.The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression.High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.
P2860
Q26798425-4A3F889C-334F-40A0-88B1-D2FD30CC1E3DQ28084872-D97F3AB6-C9D9-45CD-9AC7-C32443AFD4C0Q34448246-130E2225-6308-408F-A086-A0F766A168ECQ35667011-0CE324B5-FEA3-4AEE-A563-A26C442121F5Q36089751-9CE87826-0065-4902-9954-32F96651F030Q37534719-ED9F008A-8043-4456-A93A-84E4F8589CEAQ38667456-C729DE0C-6EDA-4A50-80F5-67AE6A99F67AQ38771880-C042D9E8-F197-4A67-B05A-F96AA0239F7AQ38833391-41AD42FA-734A-4DAA-96EA-097EB45923E0Q39202832-29D55440-FC92-4C39-B12D-C3409644F1EDQ41239908-7543AC57-E8B1-4D4A-A66E-1296733DC2F2Q42176056-5B2FC184-1C34-4640-B88A-312897D58E95Q47112301-A73C4B72-3D47-42F1-87E1-2F44451C541BQ47135859-6861F11B-7848-4D33-8BB2-34DB7D2E098FQ47669687-B6373EF1-BFEF-458A-AB6B-686EF38699AE
P2860
MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@ast
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@en
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@nl
type
label
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@ast
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@en
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@nl
prefLabel
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@ast
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@en
MiR-205 is progressively down- ...... in high-risk prostate cancer.
@nl
P2093
P2860
P50
P356
P1476
MiR-205 is progressively down- ...... r in high-risk prostate cancer
@en
P2093
Burkhard Kneitz
Charis Kalogirou
Evelyne Lerut
Hubertus Riedmiller
Martin Spahn
Maximilian Burger
Steven Joniau
Susanne Kneitz
P2860
P304
21414-21434
P356
10.3390/IJMS141121414
P407
P577
2013-10-29T00:00:00Z